FDA Approves Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel for Nonsquamous NSCLC

December 4, 2019 – The FDA has approved atezolizumab in combination with carboplatin and nab-paclitaxel for the first-line treatment of adult patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) who do not harbor EGFR or ALK molecular aberrations. The approval was based on data from the phase III IMpower130 study, which showed that the combination of atezolizumab/chemotherapy led to a median overall survival (OS) of 18.6 months … (leggi tutto)